key: cord-0760696-y4ne1q1d
authors: Alexander, Helen; Patel, Neil P.
title: Response to Martora et al.’s “Hidradenitis suppurativa flares following COVID-19 vaccination: A case series”
date: 2022-05-10
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2022.05.005
sha: 0675ddd881922d45c000475e8c9fb8ce17a29793
doc_id: 760696
cord_uid: y4ne1q1d

nan

suppurativa (HS) who experienced a flare in their condition following COVID-19 vaccination. 1 We would 26 like to report our own case of a patient who presented with HS after COVID-19 vaccination, although in 27 contrast our patient had no prior history of the disease.

The patient was a 63-year-old south Asian man who was overweight (body mass index 29.5), a non-29 smoker, and had a background of hypertension, hyperlipidaemia, ischaemic heart disease, and 

The timing of the skin lesions three weeks after both doses of the vaccine, and the lack of previous HS 46 lesions, indicates that COVID-19 vaccination was the trigger for de novo HS disease. Interestingly, the manifestation of HS was incrementally more severe after the second vaccine dose than the first dose, 

Hidradenitis suppurativa flares following 63 COVID-19 vaccination: A case series

COVID-19 vaccines: modes of immune activation and future 65 challenges

Hidradenitis Suppurativa: A Systematic Review 67

Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model

Hidradenitis suppurativa: A folliculotropic disease of innate 70 immune barrier dysfunction?